Skip to Content Skip to Search

Our focus areas

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers.

We are strengthening our pipeline through a focus on science related to the immune system, the use of human genetics and advanced technologies.

Our early stage research is not constrained by therapy areas with teams actively encouraged to follow the science. As projects progress, potential new medicines are aligned to the therapy area where data shows we can have the greatest impact to the largest number of patients.


Our work in Oncology is focused on maximising patient survival through transformational medicines. We are committed to helping those affected by cancer.

We have significantly progressed our oncology pipeline organically and through external additions with 17 programs currently in clinical development.

Our pipeline is currently focused on innovation in:

• immuno-oncology: using the human immune system to treat cancer
• cell therapy: engineering human T-cells to target cancer
• cancer epigenetics: modulating the gene-regulatory system of the epigenome to exert anti-cancer effects
 synthetic lethality: targeting two mechanisms at the same time which together, but not alone, have substantial effects against cancer

GSK Oncology has several lead therapies in our pipeline: belantamab mafodotin, an antibody drug conjugate targeting B-Cell Maturation Antigen (BCMA), which targets malignant plasma cells and is being investigated in multiple myeloma.

Another promising agent in our Oncology pipeline is the agonist immune checkpoint antibody targeting the inducible T-cell co-stimulatory receptor (ICOS) on activated T-cells. ICOS is designed to enhance a T-cell immune reaction against cancer cells.  Phase I/II data, for the therapy alone and in combination with the PD-1 blocking antibody pembrolizumab (Merck), show indications of clinical activity.

In the cell therapy space, we are developing the leading engineered cell therapy product for solid tumors using T cell receptors (TCRs) targeting NY-ESO-1. The therapy is engineered from the patient’s own T-cells and is currently being investigated in synovial sarcoma, lung cancer and multiple myeloma.

With GSK’s acquisition of TESARO, an oncology-focused biopharmaceutical company, we accelerated the expansion of our pipeline and re-entered the oncology market with Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor approved in the US and Europe for adults with recurrent ovarian cancer.

We are also actively pursuing other therapies in advanced non-small cell lung cancer, synovial sarcoma and various other solid tumours using antibodies, small molecules and cell therapies.

Find out more about our pipeline of potential new medicines (not yet approved for the listed indications anywhere in the world) on our pipeline chart

Learn more about our marketed products


We have a long-standing commitment to advancing the treatment, prevention and cure of HIV by developing innovative medicines that suppress or prevent the virus in new ways and help reduce the burden of treatment.

Our HIV business is managed through ViiV Healthcare, a global company 100% dedicated to HIV that GSK controls as majority owner, with Pfizer and Shionogi also as shareholders. Its broad portfolio of 13 antiretroviral medicines offers a wide range of therapeutic options for people living with HIV. They include Tivicay (dolutegravir) and Triumeq (abacavir/dolutegravir/lamivudine). Marking a new chapter in HIV care, Dovato (dolutegravir and lamivudine), is our second two-drug regimen (2DR) for the treatment of HIV, which is now launched in the US and authorised in Europe. For more information, refer to ViiV Healthcare

As leaders in developing HIV treatments for the future, ViiV Healthcare has an innovative pipeline of new medicines that includes 2-drug regimens, long-acting formulations and treatments for people who have limited options, and we also have early scientific efforts focused on finding a cure.

Find out more about our pipeline of potential new medicines (not yet approved for the listed indications anywhere in the world) on our pipeline chart

Learn more about our marketed products

Infectious diseases and global health

Our work to tackle infectious diseases includes bacterial, viral and parasitic infections. As part of our global health efforts, we are focusing on fighting the infectious diseases that impact children and adolescents in the developing world – in particular, malaria, tuberculosis (TB) and HIV/AIDs. 

Our world-leading centre at Tres Cantos has over 120 scientists working on potential new medicines for TB, malaria, Neglected Tropical Diseases like kinetoplastid diseases and causes of childhood diarrhoea.

Our pharmaceutical research and development currently covers the following infectious diseases:

• Bacterial infections. We are developing a potential first-in-class antibiotic with the potential to tackle the urgent public health threat from the growing resistance to antibiotics.

• Hepatitis B virus (HBV). We are using new technology to develop new medicines for HBV infection, a serious health problem that affects the liver and can lead to significant and potentially fatal health conditions, including cirrhosis, liver failure and liver cancer.

•  Influenza. We have developed an inhaled medicine Relenza (zanamivir) for the treatment of the two types of influenza that cause epidemic seasonal infections nearly every year. In addition, to help patients who have been hospitalised patients, we have also developed an intravenous formulation of the treatment Dectova (zanamivir).

Malaria.We have developed, in partnership with the Medicines for Malaria Venture, the first new single-dose treatment in over 60 years for Plasmodium vivax malaria Kozenis (tafenoquine), a type of relapsing malaria. This marks a major contribution towards efforts to eradicate the disease. We are also exploring new approaches to tackle the other forms of malaria that continue to cause significant mortality in many regions of the world.

• Tuberculosis (TB). We have a world-leading TB portfolio of medicines in early development spanning several classes that, in combination with other molecules, may be contenders to transform the TB landscape as part of a pan-TB regimen.

Find out more about our pipeline of potential new medicines (not yet approved for the listed indications anywhere in the world) on our pipeline chart

Learn more about our marketed products

Learn more about our approach in global health


We are focused on the biology of the immune system which plays a key role in causing a broad range of diseases. Our aim is to develop medicines that have the potential to alter the course of inflammatory disease.

Our current focus includes the following immuno-inflammatory diseases which are responsible for a significant health burden to patients and society:

Systemic lupus erythematosus (SLE). We have developed the first and only biologic medicine (Benlysta, belimumab) specifically approved to treat SLE, a chronic, incurable, autoimmune disease.

Eosinophilic Granulomatosis Polyangiitis (EGPA). We have developed the first targeted treatment for EGPA (Nucala, mepolizumab), a chronic rare disease that is caused by inflammation in the walls of small-to-medium sized blood vessels (vasculitis).

Rheumatoid arthritis (RA). We are developing treatments with new modes of action for RA since the symptoms which affect many patients still do not respond or have an inadequate response to currently available treatments.

Inflammatory Bowel Disease (IBD). We are developing several medicines, each with a different mode of action, to help address the two primary types of IBD: Crohn’s disease and ulcerative colitis. Both are chronic diseases associated with inflammation of the digestive system.

Systemic sclerosis (SSc). We are developing a new treatment for this inflammatory and fibrotic disease.

Find out more about our pipeline of potential new medicines (not yet approved for the listed indications anywhere in the world) on our pipeline chart

Learn more about our marketed products


We have led the way in developing modern innovative medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

Since 2012, we have launched six respiratory medicines, giving us the broadest portfolio of once-daily, inhaled respiratory medicines in our industry and the first-in-class severe eosinophilic asthma anti-IL-5 biologic.

We continue to innovate in respiratory biologics, with investigational programmes in nasal polyps, COPD and hypereosinophilic syndrome. Our biologics pipeline also includes the investigational medicines: long-acting anti-IL5 for severe eosinophilic asthma and anti-IL33 for severe asthma.

Our ambition in respiratory development is focused on finding new medicines and technologies that we hope will be able to overcome and prevent diseases of the lung and improve lung health.

Our ambition in respiratory development focuses on five areas:

• Fulfilling the full potential of our current medicines
• Treating beyond the lung in the management of COPD and asthma
• Achieving disease remission (asthma) and halting disease progression (COPD)
• Going beyond asthma and COPD in our treatment of diseases of the lung
• Preventing respiratory disease with vaccinations

Our approach to research will enable us to take transformational, rather than incremental, steps forward in the treatments we can develop as we focus our efforts on finding those medicines that can treat those patients for whom the simple act of breathing is a daily struggle. That is why we are here and why we will continue to relentlessly pursue innovative solutions, including the less obvious ones, to make better breathing for everyone a reality.

Find out more about our pipeline of potential new medicines (not yet approved for the listed indications anywhere in the world) on our pipeline chart

Learn more about our marketed products


Our investment in breakthrough vaccines technologies creates a real point of differentiation and will deliver further benefits in the future. We are pursuing a full portfolio of vaccines against respiratory syncytial virus (RSV), tailored to the different age groups most at risk of infection from the virus. Our chronic obstructive pulmonary disease (COPD) candidate vaccine marks a move away from the traditional concept of a vaccine given to healthy people to prevent a specific disease, towards the development of a disease-modifying vaccine that could reduce the frequency of COPD exacerbations and slow down the disease’s progress. We also advance our work on new formulations for our meningitis vaccines with our fully liquid meningitis candidate vaccine. We remain committed to the challenging goal of developing a single vaccine to cover the five most common meningitis serogroups of A, B, C, W and Y.

Our scientists are dedicated to fight diseases with the greatest burden on the most vulnerable communities, like malaria, tuberculosis (TB) and shigella. The biggest contribution we can make is through our science, but to have the greatest impact, we need strong collaboration with others to ensure there is always a clear path for our innovation – end to end – from lab to patient.

Together with IAVI (previously with Aeras), we are developing a TB candidate vaccine which aims to help prevent HIV-negative adults infected with latent TB from developing active pulmonary TB in a phase IIb trial.  Primary results from the trial at 11 sites in South Africa, Zambia and Kenya, showed overall vaccine efficacy of 54%. This is the first time in almost a century that a candidate vaccine demonstrates efficacy to protect against active pulmonary TB.

Our candidate vaccine against malaria, RTS,S, aims to protect children from Plasmodium falciparum malaria, which is most common in sub-Saharan Africa and responsible for most malarial deaths worldwide. RTS,S is the first and only vaccine to date to demonstrate it can help protect young children and infants in malaria-endemic areas against infection and clinical disease. It is also the world’s first vaccine against a parasite. Ghana, Kenya and Malawi have approved the use of RTS,S for malaria as part of a pilot vaccination implementation programme coordinated by the World Health Organization (WHO).

Find out more about our pipeline of potential new medicines (not yet approved for the listed indications anywhere in the world) on our pipeline chart

Learn more about our marketed products